Eisai to Launch Rapid-acting Insulin Secretagogue Glufast(R) in China
Eisai to Launch Rapid-acting Insulin Secretagogue Glufast(R) in China
Tokyo, Sept 3, 2010 - (JCN Newswire) - Eisai Co., Ltd. announced today that it launched Glufast(R) (Chinese brand name: Kuai ru tuo, generic name: mitiglinide calcium hydrate), a rapid-acting insulin secretagogue, in China on September 1. Glufast is a phenylalanine derived rapid-acting insulin secretagogue originally discovered and developed by Kissei Pharmaceutical Co., Ltd.
Read more on Japan Corporate News
Related posts:
- Diabetes Has Significant Negative Impact on Work Productivity in China and Japan
- China Faces Diabetes Epidemic
- Changing Times in China: Models Reject Traditional Chinese Medicine, Turning to Western Science to Lose Weight and Spray Away Hunger
- ELIXIR WELLNESS | NAISUMI The natural insulin MIMETIC
- Survey Data Reveals Shocking ‘Insulin Pump Postcode Lottery’